As previously disclosed on May 9, 2022, Akebia Therapeutics, Inc. (the ?Company?) announced a workforce reduction, including certain management transitions. As part of the workforce reduction, the Company entered into a retention and separation agreement with each of Michel Dahan, the Company?s Chief Operating Officer, and Nicole R. Hadas, the Company?s Senior Vice President, Chief Legal Officer and Corporate Secretary. Pursuant to the retention and separation agreements as amended on November 2, 2022 and May 3, 2023, each of Mr. Dahan and Ms. Hadas would separate from the Company effective as of July 28, 2023, or, in the event of certain specified events, the effective date of their separation would extend to January 26, 2024.

On July 26, 2023, the Company and Mr. Dahan agreed to further extend the effective date of his termination to March 22, 2024, and, in the event of certain specified events, the effective date of his termination may extend to September 22, 2024 (the ?Dahan July 2023 Amendment?). In addition, on July 26, 2023, the Company and Ms. Hadas agreed to further extend the effective date of her termination to October 6, 2023, and, in the event of certain specified events, the effective date of her termination may extend to March 22, 2024 (the ?Hadas July 2023 Amendment?).